https://wjpsonline.com/index.php/wjps/issue/feedWorld Journal of Pharmaceutical Sciences2025-10-23T11:21:15+00:00Editor-in-Chiefeditor@wjpsonline.comOpen Journal Systems<p><strong>The World Journal of Pharmaceutical Sciences (WJPS; Print ISSN: 2321-3310; Online </strong><strong>ISSN: 2321-3086)</strong> is an international, peer-reviewed monthly open-access journal published by Atom and Cell Publishers. The journal welcomes original research articles, review articles, short communications, mini-reviews, case reports, letter to the editor, guest editorial or commentaries and editorials of all aspects of pharmacy and pharmaceutical sciences.</p> <p><strong>Why publish with WJPS</strong></p> <p><strong>Impact Factor: 1.318</strong></p> <p><strong>Crossref DOI Assigned: 10.54037/WJPS</strong></p> <p><strong>Quick Quality Review: </strong>The journal has strong international team of editors and reviewers. Constructive reviews from renowned scientist and researcher at all editorial levels.</p> <p><strong>Rapid Decision and Publication:</strong> We guarantee a review of your manuscript by a panel of qualified experts within 15 days of submission. Authors that need a faster decision can request Fast Track review and get a response in 3-5 business days.</p> <p><strong>Indexing</strong>: Google Scholars; Advanced Science Index; Chemical Abstracts Service; Cosmos Impact Factor; CiteFactor; Directory of Research Journals Indexing; Eurasian Scientific Journal Index; Geneva Foundation for Medical Education and Research; Global Impact Factor; Index Copernicus; InfoBase Index; International Impact Factor Services; International Scientific Indexing; Open Academic Journals Index; Polish Scholarly Bibliography; Scholarsteer</p> <p><strong>Low Publication Fees:</strong> Comparable journals charge a huge sum for each accepted manuscript. WJPS only charges the fees necessary to recoup costs associated with running the journal.</p> <p>You may submit manuscripts online through following link <a href="https://wjpsonline.com/index.php/wjps/about/submissions" target="_blank" rel="noopener">https://wjpsonline.com/index.php/wjps/about/submissions</a> or as an email attachment to the following mail: editor.wjps@gmail.com</p>https://wjpsonline.com/index.php/wjps/article/view/1959ANALYTICAL METHOD DEVELOPMENT AND RAPID ANALYTICAL TECHNIC FOR SIMULTANEOUS ESTIMATION OF MONTELUKAST AND BILASTINE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC METHOD2025-10-17T12:47:20+00:00Dr. Subhas Sahoopolepraveen5577@gmail.com<p>A simple, Accurate, precise method was developed for the simultaneous estimation of the Bilastine and Montelukast in bulk and pharmaceutical dosage form. Chromatogram was run through Agilent C18 150 x 4.6 mm, 5mm. Mobile phase containing Buffer :Acetonitrile taken in the ratio 70:30 was pumped through column at a flow rate of 1.0 ml/min. Buffer used in this method was 0.01N Na2Hpo4 buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 265.0 nm. Retention time of Bilastine and Montelukast were found to be 2.141 min and 2.605 min. %RSD of the Bilastine and Montelukast were and found to be 0.4% and 0.2% respectively. %Recovery was obtained as 99.47% and 99.55% for Bilastine and Montelukast respectively. LOD, LOQ values obtained from regression equations of Bilastine and Montelukast were 0.1, 0.03 and 0.03, 0.10 respectively. % Assay was obtained as 99.74% and 99.72% for Bilastine and Montelukast respectively. Regression equation of is Montelukast y = 45726x + 6306.9, y = 43360x + 810 of Bilastine.</p>2025-10-17T00:00:00+00:00Copyright (c) 2025 Dr. Subhas Sahoohttps://wjpsonline.com/index.php/wjps/article/view/1962RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF TENEGLIPTIN AND REMOGLIFLOZIN IN BULK AND PHARMACEUTICAL DOSAGE FORM2025-10-17T12:57:58+00:00Dr. S. Srinivasa Raoharikas232@gmail.com<p>Simultaneous estimation of the Remogliflozin and Teneligliptin in pharmaceutical dosage form. Chromatogram was run through Discovery C18 250 x 4.6 mm, 5m. Mobile phase containing Buffer Ammonium acetate: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 0.9 ml/min.. Temperature was maintained at 30°C. Optimized wavelength selected was 229 nm. Remogliflozin and Teneligliptin were eluted at 2.139 min and 2.176 min respectively. %RSD of the Remogliflozin and Teneligliptin were and found to be 0.6 and 0.7 respectively. %Recovery was obtained as 99.50% and 99.50% for Remogliflozin and Teneligliptin respectively. LOD, LOQ values obtained from regression equations of Remogliflozin and Teneligliptin were 0.11, 0.33 and 0.005, 0.014 respectively. Regression equation of Remogliflozin is y = 52813x + 14718, and y = 69817x + 586.95 of Teneligliptin.</p>2025-10-17T00:00:00+00:00Copyright (c) 2025 Dr. S. Srinivasa Raohttps://wjpsonline.com/index.php/wjps/article/view/1960HPLC-BASED METHOD DEVELOPMENT AND VALIDATION FOR QUANTIFICATION OF NIRMATRELVIR AND RITONAVIR IN COMBINATION THERAPY2025-10-17T12:54:25+00:00Dr. S. Srinivasa Raodaramanasa676@gmail.com<p>A simple, Accurate, precise method was developed for the simultaneous estimation of the Nirmatrelvir and Ritonavir in pharmaceutical dosage form. Chromatogram was run through Kromasil C18 250 x 4.6 mm, 5. Mobile phase containing Buffer 0.1% OPA : Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 1.0ml/min. Buffer used in this method was 0.1% OPA. Temperature was maintained at 30°C. Optimized wavelength selected was 240 nm. Nirmatrelvir and Ritonavir were eluted at 2.303 min and 2.783 min respectively. %RSD of the Nirmatrelvir and Ritonavir were and found to be 0.8 and 0.5 respectively. %Recovery was obtained as 99.63% and 99.70% for Nirmatrelvir and Ritonavir respectively. LOD, LOQ values obtained from regression equations of Nirmatrelvir and Ritonavir were 0.04, 0.13 and 0.01, 0.02 respectively. Regression equation of Nirmatrelvir is y = 92901x + 3504.3, and y = 116867x + 4632.7 of Ritonavir.</p>2025-10-17T00:00:00+00:00Copyright (c) 2025 Dr. S. Srinivasa Raohttps://wjpsonline.com/index.php/wjps/article/view/1965EVALUATION OF THE ANTIASTHMATIC ACTIVITY OF AZIMA TETRACANTHA LAM LEAVES IN ANIMAL MODEL2025-10-23T11:21:15+00:00Madhu Shrigorrenkalamadhusri@gmail.com<p>Asthma is a chronic disease that affects approximately 300 million people worldwide. Although wide range of drug is available, the relief provided by them is mainly symptomatic and short lived. Moreover, the side effects of these drugs are also quite disturbing. Hence, a continuous search is on going to identify effective and safe remedies to treat bronchial asthma. Ayurveda is a great Indian tradition and have an important role in discovery of new medicines. There are many natural herbs that can be used for asthma, treatment. Azima Tetracantha Lam is traditionally used to treat asthma. Although these plants possess diverse pharmacological actions, the scientific data on anti-asthmatic actions of this plant has got little attention. An attempt has been made to evaluate antiasthamatic activity of Azima Tetracantha Lam of aqueous and alcoholic extracts of medicinal plant. Different groups of guinea pigs (350-500 g) of either sex were subjected to acetylcholine (n = 5) and histamine-induced (n = 10) airway constriction. AQEAT and ALEAT (200 and 300 mg/kg) showed potent bronchodilator activity on histamine-and acetylcholine-induced airway constriction in guinea pigs. These extract has shown the sub-effective dose produced at 100, 200 and 300 mg/kg in all the models. The LD50 of the Aqueous and Alcoholic extracts at a dose of 100, 200 and 300 mg/kg are found to be 2262.7 and 1131.4 by oral route. These LD50 values fall within the practically non-toxic range. The present study for the first time indicates anti-asthmatic, acute, sub-acute studies of Azima Tetracantha Lam medicinal plants, confirming their traditional claims. The anti-asthmatic action of Azima Tetracantha Lam could be due to the inhibition of the synthesis, release or action of histamine and acetylcholine effect.</p>2025-10-23T00:00:00+00:00Copyright (c) 2025 Madhu Shrihttps://wjpsonline.com/index.php/wjps/article/view/1961RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF PREGABALIN AND ETORICOXIB IN PHARMACEUTICAL FORMULATIONS2025-10-17T12:56:17+00:00Dr. S. Srinivasa Raoachonicalahari24@gmail.com<p>The simultaneous estimation of the Pregabalin and Etoricoxib in Tablet dosage form. Chromatogram was run through Agilent C18 150 mm (4.6 x 150mm, 5μm) Mobile phase containing Buffer 70% (Ammonium acetate ) :40% Acetonitrile was pumped through column at a flow rate of 1 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 234.0 nm. Retention time of Pregabalin and Etoricoxib were found to be 2.233 min and 2.712 min. %RSD of the Pregabalin and Etoricoxib were and found to be 0.5 and 0.5 respectively. %Recovery was obtained as 100.06% and 99.81% for Pregabalin and Etoricoxib respectively. LOD, LOQ values obtained from regression equations of Pregabalin and Etoricoxib were 0.03, 0.09 and 0.02, 0.06 respectively. Regression equation of Pregabalin is y = 33728x + 2248.7, and y = 37618x + 3978.9 of Etoricoxib.</p>2025-10-17T00:00:00+00:00Copyright (c) 2025 Dr. S. Srinivasa Rao